Investor Login

New Data on Chimerix's Brincidofovir Supports Safety and Antiviral Activity Against Multiple Life-Threatening DNA Viruses in Organ Transplant Recipients

New Data on Chimerix's Brincidofovir Supports Safety and Antiviral Activity Against Multiple Life-Threatening DNA Viruses in Organ Transplant Recipients

Three Abstracts Presented at 2014 World Transplant Congress

DURHAM, N.C., July 31, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, presented new data on its investigational antiviral, brincidofovir (BCV, CMX001), at the 2014 World Transplant Congress (WTC) in San Francisco.

Data presented at WTC support brincidofovir's antiviral activity and safety profile in hematopoietic cell transplant (HCT) and solid organ transplant recipients who were treated for viral infections including adenovirus (AdV), cytomegalovirus (CMV), BK virus, Epstein-Barr virus (EBV) and varicella zoster virus (VZV).

Chimerix - 07/31/2014

MedStar Union Memorial Hospital is First Hospital in Country to Offer Rotation Medical Rotator Cuff System for Minimally Invasive Rotator Cuff Procedures

MedStar Union Memorial Hospital is First Hospital in Country to Offer Rotation Medical Rotator Cuff System for Minimally Invasive Rotator Cuff Procedures

BALTIMORE, MD -- (Marketwired) -- 07/30/14 -- MedStar Union Memorial Hospital, part of MedStar Orthopaedics, is the first hospital in the United States to offer the Rotation Medical Rotator Cuff System, a new minimally invasive technology potentially providing relief for millions of patients suffering from rotator cuff disease.

The procedure, to be performed by Les Matthews, MD, chief of orthopaedics at MedStar Union Memorial and medical director of MedStar Orthopaedics, uses a new bioinductive implant technology that induces the formation of new tendon-like tissue to effectively treat rotator cuff tendon tears in the shoulder joint.

Rotator cuff tendon tears affect more than four million people annually in the United States and are the most common source of shoulder pain and disability. Tears occur most often from repetitive overuse of the shoulder, or from sudden stress caused by an acute injury; the risk of injury increases with age. Tears that start out small, over time, often develop into larger, more painful and debilitating tears due to continuing degeneration of the torn tendon.

Rotation Medical - 07/30/2014

Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company

Anthera to Form a New Subsidiary, Alkira Therapeutics, to Assume All Development Activities and Registration Activities as a Subsidiary of Anthera
HAYWARD, Calif., July 14, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy ("PERT") from Eli Lilly and Company. Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases. EPI is characterized by low absorption of fat and other nutrients due to a reduction in digestive enzymes produced by the pancreas.

Anthera Pharmaceuticals - 07/14/2014

CardioDx Announces Aetna and Coventry Health Coverage for Corus® CAD Gene Expression Test

- Blood-Based Test Has Potential to Improve Quality of Care and Lower Costs of Evaluation of Obstructive Coronary Artery Disease -
REDWOOD CITY, Calif. – [July 7, 2014] - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, confirmed today that Aetna has established a clinical policy for the company’s Corus® CAD gene expression test. With this decision, the Corus CAD gene expression test is eligible for coverage among Aetna and Coventry Health members. Aetna considers the Corus CAD gene expression test medically necessary for evaluation of non-diabetic adults with chest pain or anginal equivalent symptoms who have no history of obstructive coronary artery disease.

CardioDx - 07/07/2014

Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for Pediatric X-Linked Hypophosphatemia in the US and EU

NOVATO, CA – July 1, 2014 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient screened and enrolled in the Phase 2 study of the human monoclonal anti-FGF23 antibody KRN23 (UX023) in pediatric patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.

Ultragenyx Pharmaceutical - 07/01/2014

Rotation Medical Completes $27.2 Million Series B Financing

Funds to Support Commercial Launch and Post-Market Clinical Studies of Rotator Cuff System with Bioinductive Implant for Treating Rotator Cuff Disease

PLYMOUTH, MINN. — July 1, 2014 - Rotation Medical, a medical device company focused on developing new technologies to treat rotator cuff disease, today announced that it has secured $27.2 million in an oversubscribed Series B financing. Life Sciences Partners (LSP), a new investor, and New Enterprise Associates (NEA) co-led the financing, which also included new investor Pappas Ventures and others. Fouad Azzam, Ph.D., from LSP and Scott Weiner from Pappas Ventures will join the Rotation Medical Board of Directors. The funding will support the commercial launch and post-market clinical studies of the Rotation Medical rotator cuff system.

Rotation Medical - 07/01/2014

Ultragenyx Announces Results from Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults

Treatment with KRN23 induces a sustained increase in serum phosphorus and increases in bone remodeling markers

Novato, CA— June 24, 2014 — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness. The data was presented at the 2014 ICE/ENDO joint meeting of The Endocrine Society and The International Congress of Endocrinology in Chicago.

Ultragenyx Pharmaceutical - 06/24/2014

Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome

SAN DIEGO, June 17, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administrationas a treatment for myelodysplastic syndrome (MDS). Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with diffuse large B-cell lymphoma (DLBCL) and bladder cancer targeting specific genetic mutations in histone acetylation that increase the likelihood of response in tumor cells.

Mirati Therapeutics - 06/17/2014

Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents Loss of Kidney Function Following Acute Ischemic Injury

Results presented at the ERA-EDTA congress led to initiation of ongoing Phase 2 clinical study in patients undergoing cardiac surgery

MONTREAL, June 3, 2014 – Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today presented preclinical results showing that its lead development compound THR-184 can effectively protect against loss of kidney function following acute ischemic injury in rat. Results of the studies were presented at the 51st European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress taking place in Amsterdam, The Netherlands.

Thrasos Therapeutics - 06/03/2014
logo_white
veteran_logo_white
NVCA
bio
nc-biotech